Switching CD4 T Cell Fate via RNA Translational Control
One of 5,541 projects Taiyo tracks in Netherlands.
Source: EU Funding & Tenders Portal
CD4 T cells drive adaptive immunity against infection and cancer, yet in cancer they often collapse into dysfunctional states enabling disease progression. The molecular rules dictating how CD4 T cells mount protective or impaired responses remain unclear, limiting our ability to harness their full therapeutic potential. While transcriptional control has traditionally been viewed as the key determ
- Status
- Prospective
- Sector
- Hospital
- Location
- Netherlands
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Switching CD4 T Cell Fate via RNA Translational Control
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | CD4 T cells drive adaptive immunity against infection and cancer, yet in cancer they often collapse into dysfunctional states enabling disease progression. The molecular rules dictating how CD4 T cells mount protective or impaired responses remain unclear, limiting our ability to harness their full therapeutic potential. While transcriptional control has traditionally been viewed as the key determinant of T cell fate, my research reveals an equally essential, yet largely overlooked layer of regulation at the RNA translation. I show that active regulation of translation initiation and elongation drives CD4 T cell differentiation and dictates the balance between protective and dysfunctional immune responses. In this ERC proposal, I will dissect for the first time the translational circuitry that determines CD4 T cell fate across three interconnected axes of control. 1) I will define the molecular gatekeepers that select mRNAs for translation initiation. 2) I will uncover the codon-tRNA usage biases that prioritize synthesis of proteins driving distinct functional states. 3) I will identify the overall environmental cues that rewire CD4 T cell translational programs in cancer. Combining my proven expertise in advanced mouse models and state-of-the-art molecular profiling of rare primary cells, with access to innovative human T cell systems and patient-derived tumor fragments, I am uniquely positioned to reveal the principles underpinning this regulatory layer and identify new strategies to reprogram CD4 T cell states. STaR-T will move beyond the transcription-centric view of T cell biology and establish a new conceptual paradigm: RNA translation is not a passive consequence of T cell activation, but a selective, decisive checkpoint that directs T cell fate and function. My goal is to redefine our understanding of CD4 T cell responses and harness translation reprogramming to unlock the full potential of adaptive immunity in vaccination and immunotherapy against cancer. |
Location
Country | Netherlands |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-11-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Netherlands
- OSKAR
- The NL Digital Hospital
- Rosalind Franklin Biotechnology Centre, Delft, Netherlands
- HALIX cGMP Biopharmaceutical Facility, Leiden
- Fujifilm’s Cell Culture Media Manufacturing Facility, Netherlands
- SHINE Medical Isotope Production Facility, Veendam, Netherlands
- Bristol Myers Squibb’s New CAR-T Cell Therapy Facility, Leiden, Netherlands
- Celtic Medical
